| $385M | ||
| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M |
Buys | $113,450 | 4 | 40 |
Sells | $1,852,104 | 6 | 60 |
| Zaderej Karen L. | director | 4 | $113,450 | 0 | $0 | $113,450 |
| Lurker Nancy | director | 0 | $0 | 3 | $150,942 | $-150,942 |
| Ribeiro Ramiro | Chief Medical Officer | 0 | $0 | 2 | $758,922 | $-758,922 |
| Cormorant Asset Management, LP | Former 10% Owner | 0 | $0 | 1 | $942,240 | $-942,240 |
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Over the last 12 months, insiders at EyePoint Pharmaceuticals, Inc. have bought $113,450 and sold $1.85M worth of EyePoint Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at EyePoint Pharmaceuticals, Inc. have bought $22.45M and sold $32.75M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Zaderej Karen L. (director) — $113,450.
The last purchase of 5,000 shares for transaction amount of $29,950 was made by Zaderej Karen L. (director) on 2025‑05‑19.
| 2026-01-05 | Sale | Ribeiro Ramiro | Chief Medical Officer | 42,544 0.0503% | $17.10 | $727,319 | -7.40% | |
| 2025-12-04 | Sale | Cormorant Asset Management, LP | Former 10% Owner | 60,000 0.0821% | $15.70 | $942,240 | +2.15% | |
| 2025-12-04 | Sale | Lurker Nancy | director | 9,300 0.0122% | $15.11 | $140,477 | +2.15% | |
| 2025-11-28 | Sale | Lurker Nancy | director | 500 0.0007% | $14.95 | $7,475 | +14.16% | |
| 2025-11-26 | Sale | Lurker Nancy | director | 200 0.0003% | $14.95 | $2,990 | +14.23% | |
| 2025-11-11 | Sale | Ribeiro Ramiro | Chief Medical Officer | 2,722 0.0041% | $11.61 | $31,602 | +39.31% | |
| 2025-05-19 | Zaderej Karen L. | director | 5,000 0.0071% | $5.99 | $29,950 | +93.93% | ||
| 2025-05-16 | Zaderej Karen L. | director | 5,000 0.0069% | $5.81 | $29,050 | +92.82% | ||
| 2025-05-15 | Zaderej Karen L. | director | 5,000 0.0069% | $5.47 | $27,350 | +106.47% | ||
| 2025-05-14 | Zaderej Karen L. | director | 5,000 0.0072% | $5.42 | $27,100 | +114.39% | ||
| 2024-08-21 | ANDO GORAN | director | 5,000 0.0082% | $7.95 | $39,750 | -8.84% | ||
| 2024-08-20 | DICICCO WENDY F | director | 2,567 0.0048% | $7.79 | $19,997 | +6.87% | ||
| 2024-08-19 | Zaderej Karen L. | director | 12,500 0.0235% | $7.98 | $99,750 | +3.84% | ||
| 2024-08-16 | Lurker Nancy | director | 3,173 0.0057% | $7.88 | $25,003 | +3.91% | ||
| 2024-07-12 | Sale | GUYER DAVID R | director | 11,625 0.0274% | $10.06 | $116,995 | -20.62% | |
| 2024-06-03 | Sale | GUYER DAVID R | director | 11,625 0.0233% | $10.30 | $119,705 | -17.41% | |
| 2024-05-14 | Sale | GUYER DAVID R | director | 11,625 0.0227% | $12.65 | $147,045 | -33.01% | |
| 2024-05-06 | Cormorant Asset Management, LP | 10 percent owner | 850,000 1.8064% | $11.86 | $10.08M | -25.18% | ||
| 2024-04-18 | Cormorant Asset Management, LP | 10 percent owner | 581,765 1.2029% | $18.03 | $10.49M | -50.63% | ||
| 2024-02-02 | Sale | Jones David Scott | SVP & Chief Commercial Officer | 209 0.0007% | $28.49 | $5,954 | -67.70% |
| Cormorant Asset Management, LP | Former 10% Owner | 8265000 9.9834% | $124.64M | 6 | 1 | <0.0001% |
| Lurker Nancy | director | 206547 0.2495% | $3.11M | 4 | 7 | <0.0001% |
| Zaderej Karen L. | director | 36500 0.0441% | $550,420.00 | 5 | 0 | +3.84% |
| Ribeiro Ramiro | Chief Medical Officer | 0 0% | $0 | 0 | 2 | |
| EW Healthcare Partners, L.P. | 10 percent owner | 3490921 4.2167% | $52.64M | 2 | 9 | +60.73% |
| Ashton Paul | President & CEO | 440741 0.5324% | $6.65M | 0 | 12 | |
| Ocumension Therapeutics | director | 100221 0.1211% | $1.51M | 0 | 3 | |
| Liu Ye | director | 100221 0.1211% | $1.51M | 0 | 4 | |
| Freedman Lori | VP Corp. Affairs, GC and Sec | 96423 0.1165% | $1.45M | 0 | 5 | |
| Elston George | Chief Financial Officer | 40000 0.0483% | $603,200.00 | 4 | 0 | +18.73% |
| Landis John B. | director | 40000 0.0483% | $603,200.00 | 1 | 0 | <0.0001% |
| Jones David Scott | SVP & Chief Commercial Officer | 37962 0.0459% | $572,466.96 | 0 | 6 | |
| Paggiarino Dario A. | Chief Medical Officer | 36505 0.0441% | $550,495.40 | 0 | 7 | |
| Godshall Douglas Evan | director | 29500 0.0356% | $444,860.00 | 1 | 0 | <0.0001% |
| Duker Jay S. | director | 17500 0.0211% | $263,900.00 | 1 | 0 | <0.0001% |
| ANDO GORAN | director | 13150 0.0159% | $198,302.00 | 1 | 0 | <0.0001% |
| Hopper Paul | director | 10000 0.0121% | $150,800.00 | 1 | 0 | +38.89% |
| DICICCO WENDY F | director | 9967 0.012% | $150,302.36 | 1 | 0 | +6.87% |
| Pine Michael Craig | Chief Corp Dev.&Strat. Officer | 4343 0.0052% | $65,492.44 | 1 | 1 | <0.0001% |
| GUYER DAVID R | director | 1850 0.0022% | $27,898.00 | 0 | 3 | |
| Ross Leonard S | Vice President, Finance | 0 0% | $0 | 0 | 4 |
$8,217,280 | 112 | 46.33% | $1.3B | |
$607,159,124 | 92 | 3.55% | $1.32B | |
$21,345,882 | 83 | 94.45% | $1.4B | |
$14,874,415 | 78 | 37.43% | $1.18B | |
$61,783,526 | 37 | 18.57% | $1.25B | |
$678,065,999 | 37 | -13.32% | $1.34B | |
$530,111,731 | 35 | 8.69% | $1.25B | |
$104,199,091 | 28 | 16.42% | $1.39B | |
$31,271,604 | 28 | 28.69% | $1.11B | |
$150,196,329 | 28 | -8.09% | $1.23B | |
EyePoint Pharmaceuticals, Inc. (EYPT) | $121,322,364 | 24 | -6.74% | $1.25B |
$135,656,796 | 20 | 30.66% | $1.26B | |
$18,336,420 | 12 | 24.03% | $1.44B | |
$49,967,154 | 11 | 62.08% | $1.19B | |
$117,959,652 | 9 | -12.47% | $1.19B | |
$18,704,399 | 5 | -20.93% | $1.22B | |
$3,200,000 | 5 | -11.36% | $1.27B | |
$19,420,853 | 5 | 4.35% | $1.18B | |
$45,070 | 4 | 10.31% | $1.13B |
| Increased Positions | 70 | +41.42% | 10M | +14.04% |
| Decreased Positions | 68 | -40.24% | 8M | -11.23% |
| New Positions | 26 | New | 6M | New |
| Sold Out Positions | 20 | Sold Out | 2M | Sold Out |
| Total Postitions | 171 | +1.18% | 71M | +2.8% |
| Cormorant Asset Management, Lp | $145,521.00 | 10.03% | 8.32M | 0 | 0% | 2025-09-30 |
| Suvretta Capital Management, Llc | $108,249.00 | 7.46% | 6.19M | -611,376 | -8.98% | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $97,185.00 | 6.7% | 5.56M | -1M | -18.24% | 2025-09-30 |
| Blackrock, Inc. | $86,780.00 | 5.98% | 4.96M | -395,688 | -7.38% | 2025-09-30 |
| Federated Hermes, Inc. | $77,197.00 | 5.32% | 4.42M | -183,118 | -3.98% | 2025-09-30 |
| Franklin Resources Inc | $72,925.00 | 5.03% | 4.17M | -129,239 | -3% | 2025-09-30 |
| Vanguard Group Inc | $66,328.00 | 4.57% | 3.79M | -8,130 | -0.21% | 2025-09-30 |
| Tcg Crossover Management, Llc | $62,444.00 | 4.3% | 3.57M | 0 | 0% | 2025-09-30 |
| Citadel Advisors Llc | $37,327.00 | 2.57% | 2.14M | -208,821 | -8.91% | 2025-09-30 |
| Paradigm Biocapital Advisors Lp | $35,054.00 | 2.42% | 2.01M | +2M | New | 2025-09-30 |